Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Quality of Life/Cancer Control Publications

Following is a cumulative list of Hoosier Cancer Research Network publications in quality of life/cancer control.

Manuscripts and Journal Articles

  • Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumorsundergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study QL12-153. Support Care Center 2016 Feb 2 (epub ahead of print) PMID: 26838019
  • Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study QL05-37. J Clin Oncol. 2012 Nov 10;30(32):3998-4003. doi: 10.1200/JCO.2011.39.5558. Epub 2012 Aug 2
  • Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Hoosier Oncology Group Study QL05-37. Support Care Center 2007 Nov; 15(11): 1293-300.
  • Rudolph M. Navari, Lawrence H. Einhorn, Patrick J. Loehrer Sr., Steven D. Passik, Jake Vinson, John McClean, Naveed Chowhan, Nasser Hanna, Cynthia Johnson:A Phase II Trial of Olanzapine, Dexamethasone and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study QL03-70. Support Care Cancer. 2007 Mar 21: 17375339 (P,S,E,B,D)
  • Rudolph M. Navari, Lawrence H. Einhorn, Steven D. Passik, Patrick J. Loehrer Sr., Cynthia Johnson, M. L. Mayer, J. McClean, Jake Vinson, W. Pletcher; A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study QL01-26. Support Care Cancer. 2005 Jul;13(7):529-34. Epub 2005 Feb 8. PMID: 15700131
  • MJ Fisch, JL Kristeller, S Passik, PJ Loehrer, LH Einhorn. Trial of Antidepressants for Mildly Depressed Cancer Patients Should Have Been Reported in a Manner Allowing Independent Evaluation of Investigators’ Claims. Journal of Clinical Oncology, Vol 22, No 4 (February 15), 2004: pp 749-758
  • Passik SD. Navari RM. Jung SH. Nagy C. Vinson J. Kirsh KL. Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study QL00-4. Cancer Investigation. 22(3):383-8, 2004.
  • Michael J. Fisch, Patrick J. Loehrer, Jean Kristeller, Steven Passik, Sin-Ho Jung, Jianzhao Shen, Matthew A. Arquette, Mary J. Brames, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group QL97-1. J Clin Oncology Vol 21, Issue 10 (May), 2003: 1937-1943.
  • Michael J. Fisch, Michael L. Titzer, Jean L. Kristeller, Jianzao Shen, Patrick J. Loehrer, Sin-Ho Jung, Steven D. Passik, and Lawrence H. Einhorn. Assessment of Quality of Life in Outpatients with Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being: A Hoosier Oncology Group Study. J Clin Oncology, Vol 21, Issue 14 (July), 2003: 2754-2759
  • SD Passik, J Lundberg, KL Kirsh, D Theobald, K Donaghy, E Holtsclaw, M Cooper, W Dugan. A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain. QL01-26 Journal of Pain and Symptom Management Vol. 23 No. 6 June 2002: 526-32

Abstracts, Posters, and Presentations

  • Brames MJ, Case-Eads S, Hanna NH, Fausel CA, Breen T, Einhorn LH. Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study QL12-153. Accepted as an electronic publication at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr e20737)
  • Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted for poster presentation at the MASCC/ ISOO Annual Meeting on Supportive Care in Cancer, June 25-27, 2015, Copenhagen Denmark.
  • C. Albany, N.H. Hanna, J. Picus, R.J. Hauke, C.A. Fausel, Z. Liu, M.J. Brames, L.H. Einhorn. Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4594)
  • M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation (Abstract # A-327-0011-00199) to the 2011 International Symposium of the Multinational Association of Supportive Care in Cancer, June 23-25, Athens, Greece.
  • M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn.
    Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation at the Oral Abstract Session (Abstract # 9013) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
  • M.J. Brames, E. Johnston, C.R. Nichols, J. Picus, D.J. Vaughn, C.A. Fausel, T.E. Breen, M. Yu, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as a Poster Presentation at the International Symposium of the Multinational Association of Supportive Care in Cancer, June 24-26, 2010 Vancouver, Canada.
  • R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV) QL03-70. Accepted as a poster presentation at the ASCO Annual Meeting, June 2-6, 2006, Atlanta, GA. J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 8608
  • R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, M. L. Mayer, W. Pletcher, J. McClean. A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: Hoosier Oncology Group QL01-26. Presented as a poster discussion at the ASCO annual meeting June 5-8, 2004, New Orleans, LA. J Clin Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 8046
  • Steve Passik, Patrick Loehrer, Rudolph Navari, Cindy Nagy, Jeanette Sawi, SinHo Jung; A Phase I Trial of Olanzapine (ZYPREXA) For the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: A Hoosier Oncology Group Study QL00-4. Accepted as a poster presentation for ASCO annual meeting May 18-21, 2002, Orlando, FL.
  • Michael L. Titzer, Michael Fisch, Jean L. Kristeller, Sin-Ho Jung, Patrick J. Loehrer, Lawrence H. Einhorn. Clinicians’ Assessment Of Quality Of Life (QoL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.
  • Michael J. Fisch, Patrick J. Loehrer, Steven D. Passik, Jean L. Kristeller, Sin-Ho Jung, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial of the Hoosier Oncology Group QL97-1. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.
  • R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting: Hoosier Oncology Group QL03-70. Accepted to the ASCO annual meeting June 2-6, 2006, Atlanta, Georgia